ExcellGene SA, privately held and founded 2001, offers services in research, development and manufacturing for the biopharmaceutical industry. The Company announces today its role in the recently approved consortium funding through the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership of .
Epidemiologists say the window to approve a new Omicron-targeting vaccine before a third wave hits is closing fast and Australia should approve a wider rollout of a fourth booster shot.
The University of Sydney is a lead partner in an international consortium awarded up to US$19.3 million by The Coalition for Epidemic Preparedness Innovations to support the development of a 'variant-proof' SARS-CoV-2 vaccine candidate.The multidisci
The University of Sydney is a lead partner in an international consortium awarded up to US$19.3 million by The Coalition for Epidemic Preparedness Innovations to support the development of a 'variant-proof' SARS-CoV-2 vaccine candidate.The multidisci